Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer

NCT03054363 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03054363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03054363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 1/2
Overall status
Completed
Start date
November 27, 2017
Completion date
February 7, 2023
Enrollment
42 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer